Alzheimer’s Disease

Neuropsychiatric and behavioral markers of dementia risk

Directions for blood biomarker research for early AD diagnosis

Discovery and validation of novel drug targets involved in neuroinflammation

Investigating CT1812: an S2R modulator in development for Alzheimer’s disease

Progress in the Davos Alzheimer’s Collaborative’s Global Cohort Development program

The inter-relationship between delirium and dementia

Investigational S2R modulator CT1812 affects key proteins in Alzheimer’s disease

The Davos Alzheimer’s Collaborative

Using digital technology to build a truly global cohort in Alzheimer’s disease

Phase II study of S2R modulation in patients with dementia with Lewy bodies

Considering non-cognitive markers in dementia

Prognostic blood biomarkers in the pre-clinical stages of Alzheimer’s disease

Guiding patients on intermittent fasting for brain health

TOGETHER study: updates on bepranemab as a potential treatment for AD

The use of technology to reduce loneliness and social isolation in older adults

What do we understand about the secretion of brain p-tau in AD?